The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells.
暂无分享,去创建一个
G. Morgan | F. Davies | J. Child | S. Richards | G. Pratt | J. Fenton | A. Jack | A. Rawstron | R. Owen | J. Ashcroft | R. Owen | R. Jones | A. English | A. English | Richard A. Jones
[1] Philippe Moreau,et al. CD130 rather than CD126 expression is associated with disease activity in multiple myeloma , 1999, British journal of haematology.
[2] B. Ness,et al. Prognostic significance of the S‐phase fraction of light‐chain‐restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on eastern cooperative oncology group treatment trial E9486 , 1999, American journal of hematology.
[3] R. Bataille,et al. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. , 1999, Blood.
[4] T. Robak,et al. Circulating IL‐6‐type cytokines and sIL‐6R in patients with multiple myeloma , 1999, British journal of haematology.
[5] A. Órfão,et al. Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. , 1999, Pathologie-biologie.
[6] N. Nissen,et al. S-phase induction by interleukin-6 followed by chemotherapy in patients with refractory multiple myeloma. , 1998, Leukemia research.
[7] S. Rose-John,et al. The Membrane Proximal Cytokine Receptor Domain of the Human Interleukin-6 Receptor Is Sufficient for Ligand Binding but Not for gp130 Association* , 1998, The Journal of Biological Chemistry.
[8] I. Rensink,et al. Chimaeric anti‐interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose‐escalating study , 1998, British journal of haematology.
[9] Joan,et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. , 1998, The American journal of pathology.
[10] H. Ishikawa,et al. Cyclin D1 and p16INK4A are preferentially expressed in immature and mature myeloma cells, respectively , 1997, British journal of haematology.
[11] M. Goldsmith,et al. A Kaposi’s Sarcoma-associated Herpesvirus-encoded Cytokine Homolog (vIL-6) Activates Signaling through the Shared gp130 Receptor Subunit* , 1997, The Journal of Biological Chemistry.
[12] J. Said,et al. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. , 1997, Science.
[13] G. Morgan,et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage , 1997, British journal of haematology.
[14] R. Ohno,et al. Erythropoietin receptor expression on human bone marrow erythroid precursor cells by a newly‐devised quantitative flow‐cytometric assay , 1997, British journal of haematology.
[15] R. Greil,et al. Constituents of autocrine IL‐6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies , 1996, International journal of cancer.
[16] M. Laakso,et al. Soluble interleukin‐6 receptor as a prognostic factor in multiple myeloma , 1996, British journal of haematology.
[17] A. Kuramoto,et al. High proportions of VLA‐5− immature myeloma cells correlated well with poor response to treatment in multiple myeloma , 1995, British journal of haematology.
[18] B. Klein,et al. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. , 1995, Blood.
[19] B. Klein,et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. , 1995, Blood.
[20] A. Lichtenstein,et al. Interleukin-6 inhibits apoptosis of malignant plasma cells. , 1995, Cellular immunology.
[21] K. Anderson,et al. CD40 ligand triggered interleukin-6 secretion in multiple myeloma. , 1995, Blood.
[22] A. Kuramoto,et al. Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. , 1995, Blood.
[23] Marcos González,et al. A New Staging System for Multiple Myeloma Based on the Number of S-Phase Plasma Cells , 1995 .
[24] R. V. van Oers,et al. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. , 1994, Blood.
[25] G. Ciliberto,et al. Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. , 1994, Blood.
[26] B. Klein,et al. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130 , 1994, The Journal of experimental medicine.
[27] Y. Shima,et al. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130 , 1994, The Journal of experimental medicine.
[28] H. Harada,et al. Identification of immature and mature myeloma cells in the bone marrow of human myelomas , 1993 .
[29] J. Woodliff,et al. Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells , 1993 .
[30] B. Klein,et al. Increased and highly stable levels of functional soluble interleukin‐6 receptor in sera of patients with monoclonal gammopathy , 1993, European journal of immunology.
[31] R. Brown,et al. Interleukin-6 receptor expression and saturation on the bone marrow cells of patients with multiple myeloma. , 1993, Leukemia.
[32] R. Kyle,et al. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. , 1992, Cytokine.
[33] B. Klein,et al. In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma , 1991, European journal of immunology.
[34] T. Hirano,et al. Molecular cloning and expression of an IL-6 signal transducer, gp130 , 1990, Cell.
[35] J. Miyazaki,et al. IgG1 plasmacytosis in interleukin 6 transgenic mice. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[36] H. Asaoku,et al. BSF‐2/IL‐6 does not augment lg secretion but stimulates proliferation in myeloma cells , 1989, American journal of hematology.
[37] C. Morimoto,et al. Response patterns of purified myeloma cells to hematopoietic growth factors. , 1989, Blood.
[38] M. Jourdan,et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. , 1989, Blood.
[39] J. Gerdes,et al. Determination of the growth fraction in monoclonal gammopathy with the monoclonal antibody Ki‐67 , 1988, British journal of haematology.
[40] T. Taniguchi,et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin , 1986, Nature.
[41] M. Urashima,et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. , 1997, Blood.
[42] E. Vitetta,et al. Immunotherapy of multiple myeloma , 1995, Stem cells.
[43] 原田 浩徳. Phenotypic difference of normal plasma cells from mature myeloma cells , 1993 .